India's Largest Database on New Projects
Aurobindo gets USFDA nod
26 April 2011: Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Delayed- Release tablets.
The tablets – which are the generic equivalent of Abbott Laboratories' Depakote Delayed-Release Tablets - fall under the neurological therapeutic category. They are indicated for the treatment of the manic episodes associated with bipolar disorder; as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures and for prophylaxis of migraine headaches.
Source: Hindu Business Line